ネフローゼ症候群研究ネットワーク (NEPTUNE)
希少疾患臨床研究ネットワーク傘下のネフローゼ症候群研究ネットワーク
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not surprising that the available therapies are imperfect. The therapies lack a clear biological basis, and as many families have experienced, they are often not beneficial, and in fact may be significantly toxic. Given these observations, it is essential that research be conducted that address these serious obstacles to effectively caring for patients.
In response to a request for applications by the National Institutes of Health, Office of Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a number of affiliated universities joined together with The NephCure Foundation the NIDDK, the ORDR, and the University of Michigan in collaboration towards the establishment of a Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium.
Through this consortium the investigators hope to understand the fundamental biology of these rare diseases and aim to bank long-term observational data and corresponding biological specimens for researchers to access and further enrich.
調査の概要
詳細な説明
Idiopathic Nephrotic Syndrome (NS) is a rare disease syndrome responsible for approximately 12% of all causes of end-stage kidney disease (ESRD) and up to 20% of ESRD in children. Treatment strategies for Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD) and Membranous Nephropathy (MN), the major causes of NS, include high dose prolonged steroid therapy, cyclophosphamide, cyclosporine A, tacrolimus, mycophenolate mofetil and other immunosuppressive agents, which all carry significant side effects. Failure to obtain remission using the current treatment approaches frequently results in progression to ESRD with its associated costs, morbidities, and mortality. In the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry, half of the pediatric patients with Steroid Resistant Nephrotic Syndrome required renal replacement therapy within two years of being enrolled in the disease registry. FSGS also has a high recurrence rate following kidney transplantation (30-40%) and is the most common recurrent disease leading to allograft loss.
The prevailing classification of Nephrotic Syndrome categorizes patients into FSGS, MCD, and MN, if in the absence of other underlying causes, glomerular histology shows a specific histological pattern. This classification does not adequately predict the heterogeneous natural history of patients with FSGS, MCD, and MN. Major advances in understanding the pathogenesis of FSGS and MCD have come over the last ten years from the identification of several mutated genes responsible for causing Steroid Resistant Nephrotic Syndrome (SRNS) presenting with FSGS or MCD histopathology in humans and model organisms. These functionally distinct genetic disorders can present with indistinguishable FSGS lesions on histology confirming the presence of heterogeneous pathogenic mechanisms under the current histological diagnoses.
The limited understanding of FSGS, MCD, and MN biology in humans has necessitated a descriptive classification system in which heterogeneous disorders are grouped together. This invariably consigns these heterogeneous patients to the same therapeutic approaches, which use blunt immunosuppressive drugs that lack a clear biological basis, are often not beneficial, and are complicated by significant toxicity. The foregoing shortcomings make a strong case that concerted and innovative investigational strategies combining basic science, translational, and clinical methods should be employed to study FSGS, MCD, and MN. It is for these reasons that the Nephrotic Syndrome Study Network is established to conduct clinical and translational research in patients with FSGS/MCD and MN.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Chrysta C. Lienczewski, BS
- 電話番号:734-615-5021
- メール:NEPTUNE-Study@umich.edu
研究連絡先のバックアップ
- 名前:Amanda Williams, BS
- 電話番号:734-615-5017
- メール:NEPTUNE-Study@umich.edu
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90227
- 募集
- University of Southern California-Children's Hospital
-
主任研究者:
- Kevin Lemley, MD, PhD
-
コンタクト:
- Sharon Tang, BSN
- 電話番号:323-361-7299
- メール:shatang@chla.usc.edu
-
Palo Alto、California、アメリカ、94304
- 募集
- Stanford University School of Medicine
-
コンタクト:
- Kshama Mehta, PhD
- 電話番号:650-736-1822
- メール:krmehta@stanford.edu
-
主任研究者:
- Richard Lafayette, MD
-
San Francisco、California、アメリカ、94158
- まだ募集していません
- University of California San Francisco Benioff Children's Hospitals
-
主任研究者:
- Paul Brakeman, MD, PhD
-
コンタクト:
- Daniel Schrader
- メール:daniel.schrader@ucsf.edu
-
Torrance、California、アメリカ、90502
- 募集
- Lundquist Biomedical Research Institute at Harbor UCLA Medical Center
-
コンタクト:
- Janine LaPage
- 電話番号:310-222-4104
- メール:jlapage@labiomed.org
-
主任研究者:
- Sharon Adler, MD
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- まだ募集していません
- Children's Hospital Colorado
-
コンタクト:
- Nathan Rogers
- メール:Nathan.Rogers@childrenscolorado.org
-
副調査官:
- Gabriel Cara-Fuentes, MD
-
Aurora、Colorado、アメリカ、80045
- まだ募集していません
- University of Colorado Anschutz School of Medicine
-
主任研究者:
- Amber Podoll, MD
-
コンタクト:
- Elizabeth Wagner
- メール:elizabeth.c.wagner@cuanschutz.edu
-
-
Florida
-
Miami、Florida、アメリカ、33136
- 募集
- University of Miami Miller School of Medicine
-
コンタクト:
- Carlos Bidot
- 電話番号:305-243-8973
- メール:cbidot2@miami.edu
-
主任研究者:
- Alessia Fornoni, MD. PhD
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University and Children's Healthcare of Atlanta
-
主任研究者:
- Laurence Greenbaum, MD, PhD
-
コンタクト:
- Emily Yun
- 電話番号:404-712-9998
- メール:emily.yun@emory.edu
-
-
Illinois
-
Chicago、Illinois、アメリカ、60680
- 募集
- John Stroger Cook County Hospital
-
コンタクト:
- Mathew Itteera
- 電話番号:312-864-4614
- メール:mitteera@cookcountyhhs.org
-
主任研究者:
- Ambarish Athavale, MD
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- 募集
- University of Kansas Medical Center
-
コンタクト:
- Catherine Creed
- メール:ccreed@kumc.edu
-
主任研究者:
- Ellen McCarthy, MD
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- 募集
- Johns Hopkins Medical Institute
-
コンタクト:
- Sara Boynton
- 電話番号:443-287-9051
- メール:sboynto3@jhmi.edu
-
主任研究者:
- Alicia Neu, MD
-
副調査官:
- Michael Choi, MD
-
Bethesda、Maryland、アメリカ、20892
- 完了
- Kidney Disease Section, NIDDK, NIH
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 募集
- University of Michigan Medical Center
-
コンタクト:
- Chrysta C. Lienczewski, BS - adult
- 電話番号:734-615-5021
- メール:boridley@med.umich.edu
-
主任研究者:
- Matthias Kretzler, MD
-
コンタクト:
- Amanda Williams, BS - adult
- 電話番号:734-615-5017
- メール:amwi@umich.edu
-
Ann Arbor、Michigan、アメリカ、48109
- 募集
- CS Mott Children's Hospital, University of Michigan
-
副調査官:
- Debbie Gipson, MD, MS
-
コンタクト:
- Hailey Desmond, MS
- 電話番号:734-232-4851
- メール:heturner@umich.edu
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 完了
- Mayo Clinic
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64108
- 募集
- Children's Mercy Hospital
-
主任研究者:
- Tarak Srivastava, MD
-
コンタクト:
- Kelsey Markus
- メール:kemarkus@cmh.edu
-
St Louis、Missouri、アメリカ、63110
- まだ募集していません
- Washington University - St Louis
-
コンタクト:
- Leslie Walther
- メール:leslie.walther@wustl.edu
-
主任研究者:
- Vikas Dharnidharka, MD, PhD
-
-
New York
-
New Hyde Park、New York、アメリカ、11040
- 募集
- Cohen Children's Hospital
-
主任研究者:
- Christine Sethna, MD
-
コンタクト:
- Suzanne Vento, BSN
- 電話番号:718-470-3499
- メール:svento@northwell.edu
-
New York、New York、アメリカ、10032
- 募集
- Columbia University Medical Center
-
主任研究者:
- Andrew Bomback, MD, MPH
-
コンタクト:
- Anup Pradhan
- 電話番号:212-305-6842
- メール:arp2209@cumc.columbia.edu
-
New York、New York、アメリカ、10010
- 募集
- New York University Medical Center
-
コンタクト:
- Frank Modersitzki, MPH - adult
- 電話番号:6379 212-686-7500
- メール:Frank.Modersitzki@va.gov
-
主任研究者:
- Olga Zhadnova, MD
-
主任研究者:
- Howard Trachtman, MD
-
コンタクト:
- Laura Jane Pehrson - peds
- メール:laurajane.pehrson@nyulangone.org
-
New York、New York、アメリカ、10016
- 募集
- Bellevue Hospital
-
コンタクト:
- Frank Modersitzki, MPH
- 電話番号:6379 212-686-7500
- メール:Frank.Modersitzki@va.gov
-
主任研究者:
- Laura Barisoni, MD
-
副調査官:
- Olga Zhadnova, MD
-
New York、New York、アメリカ、10016
- 募集
- New York University Veterans Administration
-
コンタクト:
- Frank Modersitzki, MPH
- 電話番号:6379 212-686-7500
- メール:Frank.Modersitzki@va.gov
-
主任研究者:
- Laura Barisoni, MD
-
副調査官:
- Olga Zhadnova, MD
-
The Bronx、New York、アメリカ、11040
- 募集
- Montefiore Medical Center
-
コンタクト:
- Patti Flynn, RN
- 電話番号:718-655-1120
- メール:pflynn@montefiore.org
-
副調査官:
- Robert Woroniecki, MD
-
主任研究者:
- Frederick Kaskel, MD
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- 募集
- University of North Carolina at Chapel Hill
-
コンタクト:
- Anne Froment
- 電話番号:919-923-1382
- メール:Anne_Froment@med.unc.edu
-
主任研究者:
- Patrick H. Nachman, MD
-
副調査官:
- Susan L. Hogan, PhD, MPH
-
副調査官:
- Keisha Gibson, MD
-
コンタクト:
- Fernanda Ochoa
- メール:ferochoa@email.unc.edu
-
Charlotte、North Carolina、アメリカ、28203
- 募集
- Atrium Health Levine Children's Hospital
-
主任研究者:
- Susan Massengill, MD
-
コンタクト:
- Layla Lo
- メール:nkauj.lo@atriumhealth.org
-
Winston-Salem、North Carolina、アメリカ、27157
- 引きこもった
- Wake Forest School of Medicine
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- 募集
- Cleveland Clinic
-
副調査官:
- Katherine Dell, MD
-
コンタクト:
- Stefanie Larson
- メール:larsons2@ccf.org
-
コンタクト:
- Villarreal
-
Cleveland、Ohio、アメリカ、44106
- 完了
- University Hospital Rainbow Babies & Children's Hospital
-
Cleveland、Ohio、アメリカ、44109
- 完了
- MetroHealth Hospital at Case Western Medical Center
-
Columbus、Ohio、アメリカ、43210
- 募集
- The Ohio State University Wexner Medical Center
-
コンタクト:
- Alexander Price
- メール:alexander.price2@osumc.edu
-
主任研究者:
- Salem Almaani, MD
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- University of Pennsylvania
-
コンタクト:
- Krishna Kallem, MD - adult, MS
- 電話番号:484-358-0315
- メール:krishna.kallem@uphs.upenn.edu
-
主任研究者:
- Lawrence Holzman, MD
-
コンタクト:
- Aliya Edwards - peds
- メール:EdwardsA1@chop.edu
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- Children's Hospital of Philadelphia
-
副調査官:
- Kevin Meyers, MD
-
コンタクト:
- Alilya Edwards
- メール:EdwardsA1@chop.edu
-
Philadelphia、Pennsylvania、アメリカ、19140
- 募集
- Temple University
-
コンタクト:
- Zoe Pfeffer, BS
- 電話番号:215-707-4712
- メール:zoe.pfeffer@tuhs.temple.edu
-
主任研究者:
- Crystal Gadegbeku, MD
-
主任研究者:
- Iris Lee, MD
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- 募集
- Medical University of South Carolina
-
主任研究者:
- David Selewski, MD, MS
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- 募集
- University of Texas-Southwestern
-
主任研究者:
- Kamal Sambandam, MD
-
コンタクト:
- Elizabeth Robles
- メール:elizabeth.robles@utsouthwestern.edu
-
Houston、Texas、アメリカ、77030
- 募集
- Texas Children's Hospital - Baylor College of Medicine
-
コンタクト:
- Aisha Deslandes
- メール:aisha.deslandes@bcm.edu
-
主任研究者:
- Shweta S. Shah, MD
-
-
Washington
-
Seattle、Washington、アメリカ、98195
- 募集
- University of Washington
-
主任研究者:
- Peter J. Nelson, MD
-
コンタクト:
- Linda Manahan, BSN
- メール:lmanahan@nephrology.washington.edu
-
Seattle、Washington、アメリカ、98145
- 募集
- Seattle Children's Hospital
-
副調査官:
- Sangeeta Hingorani, MD
-
コンタクト:
- Emily Pao
- メール:emily.pao@seattlechildrens.org
-
Spokane、Washington、アメリカ、99204
- 募集
- Providence Medical Research Center
-
コンタクト:
- Ann Cooper, CCRC
- 電話番号:509-474-4327
- メール:Ann.Cooper@providence.org
-
副調査官:
- Katherine Tuttle, MD
-
コンタクト:
- Kelli Kuykendall, CCRC
- 電話番号:509-474-4320
- メール:Kelli.Kuykendall@providence.org
-
-
-
-
Ontario
-
Richmond Hill、Ontario、カナダ、L4C 4Z3
- 完了
- York Central Hospital
-
Scarborough Village、Ontario、カナダ、M1H 3G4
- 完了
- Scarborough Hospital
-
Toronto、Ontario、カナダ、M4N 3M5
- 募集
- Sunnybrook Hospital
-
主任研究者:
- Michelle Hladunewich, MD
-
コンタクト:
- Rhea O'Neill
- メール:rhea.oneill@sri.utoronto.ca
-
Toronto、Ontario、カナダ、L5M 2N1
- 募集
- Credit Valley Hospital
-
副調査官:
- Phillip Boll, MD
-
コンタクト:
- Martin Romano, MD
- 電話番号:416-340-3514
- メール:martin.romano@thp.ca
-
Toronto、Ontario、カナダ、M5G2C4
- 募集
- University Health Network
-
コンタクト:
- Paul Ling, MD
- 電話番号:416-340-3514
- メール:pling@uhnresearch.ca
-
コンタクト:
- Martin Romano, MD
- メール:Martin.Romano@trilliumhealthpartners.ca
-
主任研究者:
- Daniel Cattran, MD
-
副調査官:
- Heather Reich, MD
-
副調査官:
- Michelle Hladunewich, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients with signs and symptoms of kidney disease consistent with FSGS, MCD, MN or proteinuric renal disease or pediatric participants not previously biopsied, who present for patient care at participating clinical centers will be eligible for Cohort A (biopsy cohort) study population targeted for enrollment into the NEPTUNE study.
To establish a cohort of pediatric participants with incident nephrotic syndrome, Cohort B, a non-biopsy cohort has been initiated for Protocol V4.0. This population, <19 years of age, presenting for nephrotic syndrome and less than 30 days of immunosuppression therapy exposure, will also be targeted for enrollment into the cNEPTUNE study.
Potential participants willing to receive their initial care and subsequent follow-up study visits at one of these sites are welcome to participate.
説明
Cohort A (biopsy cohort) Inclusion Criteria:
Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:
- Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit.
- Scheduled renal biopsy
Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:
-
Age <19 years of age
-
Initial presentation with <30 days immunosuppression therapy
-
Proteinuria/nephrotic
- UA>2+ and edema OR
- UA>2+ and serum albumin <3 OR
- UPC > 2g/g and serum albumin <3
Exclusion Criteria (Cohort A&B):
- Prior solid organ transplant
- A clinical diagnosis of glomerulopathy without diagnostic renal biopsy
- Clinical, serological or histological evidence of systemic lupus erythematosus (SLE) as defined by the ARA criteria. Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)
- Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)
- Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months
- Unwillingness or inability to give a comprehensive informed consent
- Unwillingness to comply with study procedures and visit schedule
- Institutionalized individuals (e.g., prisoners)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
FSGS/MCD Cohort (Cohort A)
Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD. Eligible participants must be scheduled for a clinically indicated renal biopsy. |
Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete. |
|
MN Cohort (Cohort A)
Membranous Nephropathy (MN) Cohort Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN. Eligible participants must be scheduled for a clinically indicated renal biopsy. |
Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete. |
|
Other glomerulopathies cohort
Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group. Eligible participants must be scheduled for a clinically indicated renal biopsy. |
Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete. |
|
cNEPTUNE (Cohort B)
Participants < 19 years of age, with < 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Event rate of change in urinary protein excretion and renal function.
時間枠:60 months
|
Defined as remission, partial remission and non-remission |
60 months
|
|
Rate of change in renal function.
時間枠:60 months
|
Defined as:
|
60 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Quality of Life:
時間枠:60 months
|
Patient-reported outcome will be assessed using Quality of Life questionnaires at regular intervals as stipulated in the visit calendar using the SF-36, PedsQL and the Patient Reported Outcome Measurement Information System (PROMIS) (in the age-appropriate groups). |
60 months
|
|
Malignancies
時間枠:60 months
|
Any cancer diagnosis of the skin, hematopoietic system, or solid organ after enrollment in NEPTUNE |
60 months
|
|
Infections, Serious and Systemic
時間枠:60 months
|
Infections including one of the following:
|
60 months
|
|
Thromboembolic Events
時間枠:60 months
|
Documented diagnosis of one of the following:
|
60 months
|
|
Hospitalization
時間枠:60 months
|
Documented hospital admission, including observation for ≥24 hours. |
60 months
|
|
Emergency Department/ Observation Unit Visit
時間枠:60 months
|
Documented visit to an emergency department or observation unit that does not lead to hospitalization and is less than 24 hours. |
60 months
|
|
Acute Kidney Injury
時間枠:60 months
|
Documented diagnosis of acute kidney injury as defined by the AKIN (Mehta et al., Critical Care 2007, 11:R31) and/or renal failure requiring renal replacement therapy <3 months. |
60 months
|
|
Death
時間枠:60 months
|
|
60 months
|
|
New Onset Diabetes
時間枠:60 months
|
Diagnosis of diabetes as indicated by 1 or more of the following not present at NEPTUNE Enrollment:
|
60 months
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Matthias Kretzler, MD、University of Michigan
出版物と役立つリンク
一般刊行物
- Wang CS, Troost JP, Wang Y, Greenbaum LA, Gibson K, Trachtman H, Srivastava T, Reidy K, Kaskel F, Sethna CB, Meyers K, Dell KM, Tran CL, Hingorani S, Lemley KV, Lin JJ, Gipson DS. Determinants of medication adherence in childhood nephrotic syndrome and associations of adherence with clinical outcomes. Pediatr Nephrol. 2022 Jul;37(7):1585-1595. doi: 10.1007/s00467-021-05176-8. Epub 2021 Nov 18.
- Solagna F, Tezze C, Lindenmeyer MT, Lu S, Wu G, Liu S, Zhao Y, Mitchell R, Meyer C, Omairi S, Kilic T, Paolini A, Ritvos O, Pasternack A, Matsakas A, Kylies D, Wiesch JSZ, Turner JE, Wanner N, Nair V, Eichinger F, Menon R, Martin IV, Klinkhammer BM, Hoxha E, Cohen CD, Tharaux PL, Boor P, Ostendorf T, Kretzler M, Sandri M, Kretz O, Puelles VG, Patel K, Huber TB. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs. J Clin Invest. 2021 Jun 1;131(11):e135821. doi: 10.1172/JCI135821.
- Kang H, Kim DR, Jung YH, Baek CW, Park YH, In Oh J, Kim WJ, Choi GJ. Pre-warming the Streamlined Liner of the Pharynx Airway (SLIPA) improves fitting to the laryngeal structure: a randomized, double-blind study. BMC Anesthesiol. 2015 Nov 20;15:167. doi: 10.1186/s12871-015-0151-4.
- Hogan MC, Lieske JC, Lienczewski CC, Nesbitt LL, Wickman LT, Heyer CM, Harris PC, Ward CJ, Sundsbak JL, Manganelli L, Ju W, Kopp JB, Nelson PJ, Adler SG, Reich HN, Holzmann LB, Kretzler M, Bitzer M. Strategy and rationale for urine collection protocols employed in the NEPTUNE study. BMC Nephrol. 2015 Nov 17;16:190. doi: 10.1186/s12882-015-0185-3.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 6801
- 1U54DK083912 (米国 NIH グラント/契約)
- 1R01DK141114-01A1 (米国 NIH グラント/契約)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。